JOP20220021A1 - تخليق على مقياس العملية لمثبط كاليكرين في البلازما - Google Patents

تخليق على مقياس العملية لمثبط كاليكرين في البلازما

Info

Publication number
JOP20220021A1
JOP20220021A1 JOP/2022/0021A JOP20220021A JOP20220021A1 JO P20220021 A1 JOP20220021 A1 JO P20220021A1 JO P20220021 A JOP20220021 A JO P20220021A JO P20220021 A1 JOP20220021 A1 JO P20220021A1
Authority
JO
Jordan
Prior art keywords
plasma kallikrein
scale synthesis
kallikrein inhibitor
inhibitor
scale
Prior art date
Application number
JOP/2022/0021A
Other languages
English (en)
Inventor
Yahya El-Kattan
Yarlagadda S Babu
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of JOP20220021A1 publication Critical patent/JOP20220021A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)

Abstract

غير متوفر
JOP/2022/0021A 2019-08-06 2020-08-05 تخليق على مقياس العملية لمثبط كاليكرين في البلازما JOP20220021A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962883396P 2019-08-06 2019-08-06
PCT/US2020/044921 WO2021026182A1 (en) 2019-08-06 2020-08-05 Process-scale synthesis of a plasma kallikrein inhibitor

Publications (1)

Publication Number Publication Date
JOP20220021A1 true JOP20220021A1 (ar) 2023-01-30

Family

ID=74504082

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0021A JOP20220021A1 (ar) 2019-08-06 2020-08-05 تخليق على مقياس العملية لمثبط كاليكرين في البلازما

Country Status (20)

Country Link
US (1) US20220289683A1 (ar)
EP (1) EP4010320A4 (ar)
JP (1) JP2022543419A (ar)
KR (1) KR20220044276A (ar)
CN (1) CN114206839A (ar)
AR (1) AR119617A1 (ar)
AU (1) AU2020324422A1 (ar)
BR (1) BR112022002060A2 (ar)
CA (1) CA3149176A1 (ar)
CL (2) CL2022000264A1 (ar)
CO (1) CO2022002392A2 (ar)
CR (1) CR20220092A (ar)
EC (1) ECSP22016209A (ar)
IL (1) IL290113A (ar)
JO (1) JOP20220021A1 (ar)
MX (1) MX2022001608A (ar)
PE (1) PE20221009A1 (ar)
TW (1) TW202120481A (ar)
UY (1) UY38826A (ar)
WO (1) WO2021026182A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4180424A1 (en) 2014-03-07 2023-05-17 BioCryst Pharmaceuticals, Inc. Substituted pyrazoles as human plasma kallikrein inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
DE69110787T2 (de) 1990-02-28 1996-04-04 Medtronic Inc Intraluminale prothese mit wirkstoffeluierung.
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
WO2003016282A2 (en) * 2001-08-13 2003-02-27 E.I. Du Pont De Nemours And Company Substituted 1h-dihydropyrazoles, their preparation and use
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
EP2484676B1 (de) * 2008-12-18 2015-01-21 Bayer CropScience AG Tetrazolsubstituierte Anthranilsäureamide als Pestizide
EP4180424A1 (en) * 2014-03-07 2023-05-17 BioCryst Pharmaceuticals, Inc. Substituted pyrazoles as human plasma kallikrein inhibitors

Also Published As

Publication number Publication date
AR119617A1 (es) 2021-12-29
CO2022002392A2 (es) 2022-04-08
AU2020324422A1 (en) 2022-03-17
ECSP22016209A (es) 2022-06-30
CR20220092A (es) 2022-06-03
MX2022001608A (es) 2022-03-11
UY38826A (es) 2021-02-26
CN114206839A (zh) 2022-03-18
BR112022002060A2 (pt) 2022-06-07
EP4010320A1 (en) 2022-06-15
TW202120481A (zh) 2021-06-01
IL290113A (en) 2022-03-01
KR20220044276A (ko) 2022-04-07
WO2021026182A1 (en) 2021-02-11
PE20221009A1 (es) 2022-06-15
CL2022000264A1 (es) 2022-10-21
JP2022543419A (ja) 2022-10-12
CL2023000942A1 (es) 2023-11-24
US20220289683A1 (en) 2022-09-15
CA3149176A1 (en) 2021-02-11
EP4010320A4 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
MX2022007969A (es) Inhibidores de egfr.
TN2019000263A1 (en) Macrocyclic compounds as ros1 kinase inhibitors
MX2022001829A (es) Proceso de fabricación de moduladores de regulador de conductancia transmembrana de la fibrosis quística (cftr).
MX2020005484A (es) Formas solidas de un inhibidor de calicreina en plasma y sales del mismo.
GEP20207111B (en) Heteroaryl compounds for kinase inhibition
MX2019010642A (es) Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos.
EA202193015A1 (ru) Ингибиторы cdk
MX2020008842A (es) Sintesis a escala de proceso de urolitina a.
MX2022000318A (es) Indanos como inhibidores de pd-l1.
PH12021550883A1 (en) Crystalline salts of a plasma kallikrein inhibitor
JOP20190163A1 (ar) منشط nrf2
JOP20220021A1 (ar) تخليق على مقياس العملية لمثبط كاليكرين في البلازما
MX2021012286A (es) Nuevas opciones sinteticas hacia la manufactura de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6 -oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-he xahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6 h)-ona.
MX2022002017A (es) Metodo para producir derivado de heterociclideno acetamida.
EP4335500A3 (en) Methods for the synthesis of deuterated dextromethorphan
MX2021000256A (es) Metodo de preparacion de inhibidor del factor de coagulacion xia e intermediario del mismo.
IL289287A (en) Processes for making plasma kallikrein inhibitors
MX2019005723A (es) Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo.
MX2023000970A (es) Metodo de preparacion de aminofuranos.
CL2021000663A1 (es) Proceso para la producción de gas de síntesis.
MX2019014989A (es) Proceso para la preparacion de (s,s)-secoisolariciresinol diglucosido y (r,r)-secoisolariciresinol diglucosido.
MX2020005168A (es) Formas de dosificacion que contienen un inhibidor calicreina de plasma.
MX2021014245A (es) Procedimientos y productos intermedios para preparar un inhibidor de btk.
ZA202202879B (en) Process for preparing an e-selectin inhibitor intermediate
MX2022006984A (es) Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina.